Biolife Solutions INC Form 4 insider transactions

Repligen Corporation announced a definitive agreement to acquire BioLife Solutions, Inc. for a combination of cash and Repligen common stock, aiming to accelerate growth in the cell therapy market.

Sean Werner, Chief Technology Officer of Biolife Solutions Inc, reported a transaction in 275 shares of common stock on July 17, 2026.

Troy Wichterman, Chief Financial Officer of Biolife Solutions Inc, reported a transaction in 844 shares of common stock on July 7, 2026.

Aby J. Mathew, EVP & Chief Scientific Officer of Biolife Solutions Inc, reported a transaction in 516 shares of common stock on July 7, 2026.

Todd Berard, Chief Marketing Officer of Biolife Solutions Inc, reported a transaction in 293 shares of common stock on July 7, 2026.

CFO Troy Wichterman disposed of 1,026 shares of BioLife Solutions common stock to satisfy tax obligations related to restricted stock units.

Chief Marketing Officer Todd Berard reported the withholding of 356 shares of BioLife Solutions common stock to satisfy tax obligations.

EVP and Chief Scientific Officer Aby J. Mathew disposed of 627 shares of BioLife Solutions common stock to satisfy tax withholding obligations.

Major shareholder Casdin Partners Master Fund reduced its stake in BioLife Solutions by 1.2 million shares over three days.

Biolife Solutions EVP & Chief Scientific Officer, Mathew Aby J., reported a sale of 515 common shares on April 8, 2026, for $19.27 per share.

Biolife Solutions Chief Marketing Officer Todd Berard reported a transaction involving the sale of common stock.

Biolife Solutions Chief Financial Officer, Troy Wichterman, reported a transaction involving the sale of company stock.

BioLife Solutions' Chief Quality and Operations, Karen A. Foster, sold 2,577 shares of common stock under a pre-arranged 10b5-1 trading plan.

BioLife Solutions President and CEO Roderick de Greef reported a disposition of 11,101 common shares to cover tax withholding obligations related to restricted stock unit release.

BioLife Solutions' Chief Marketing Officer, Todd Berard, disposed of 1,879 common shares at $19.12 each to cover tax withholding obligations related to restricted stock unit release.

BIOLIFE SOLUTIONS INC's Chief Technology Officer, Sean Werner, disposed of 1,681 shares of common stock to cover tax withholding obligations.

BioLife Solutions' Chief Financial Officer, Troy Wichterman, disposed of 3,749 common shares to cover tax withholding obligations related to restricted stock unit release.

BioLife Solutions' Chief Human Resources Officer, Sarah Aebersold, reported a future disposition of 931 common shares to cover tax withholding obligations related to restricted stock unit vesting on March 19, 2026.

BIOLIFE SOLUTIONS Chief Quality and Operations Officer Karen A. Foster disposed of 1,907 shares of common stock to cover tax obligations related to restricted stock units.

BIOLIFE SOLUTIONS EVP & Chief Scientific Officer Aby J. Mathew disposed of 2,255 common shares to cover tax withholding obligations.

BioLife Solutions' Chief Technology Officer, Sean Werner, sold 111 shares of common stock on March 3, 2026, to cover tax withholding obligations.

BioLife Solutions' Chief Quality and Operations Officer, Karen A. Foster, sold 418 shares of common stock to cover tax withholding obligations.

BioLife Solutions' EVP & Chief Scientific Officer, Aby J. Mathew, sold 529 shares of common stock to cover tax withholding obligations.

BioLife Solutions' CFO, Troy Wichterman, sold 588 shares of common stock at $20.74 per share to cover tax withholding obligations.

BIOLIFE SOLUTIONS' Chief Human Resources Officer, Sarah Aebersold, sold 219 shares of common stock at $20.74 per share to cover tax withholding obligations.

BioLife Solutions' Chief Marketing Officer, Todd Berard, sold 353 shares of common stock to cover tax withholding obligations.

BioLife Solutions Chief Marketing Officer Todd Berard increased his direct beneficial ownership of common stock through restricted stock grants, partially offset by shares withheld for taxes.

Amy DuRoss, a Director at BioLife Solutions Inc., acquired 8,170 shares of common stock through a restricted stock grant.

BioLife Solutions' Chief Financial Officer, Troy Wichterman, received substantial restricted stock awards, reflecting performance and future compensation.

BioLife Solutions Director Anthony Hunt acquired 8,170 shares of common stock, increasing his direct beneficial ownership to 15,046 shares.